EC Number   |
Application |
Reference |
|---|
    2.4.1.258 | medicine |
identification of an additional open-reading frame of 141 bp (AAGRP) in the coding region of ALG3 in a patient with congenital disorder of glycosylation. Expression of this hybrid protein is significantly increased due to the homozygous variant c.160_196del. Patient shows secondary microcephaly, significantly decreased head control and axial muscular hypotonia associated with increased limb stiffness. Frequent episodes of hyperextension are observed |
759330 |
| 2.4.1.258 | medicine |
two Vietnamese siblings with confirmed ALG3-Congenital disorders of glycosylation, 15 and 21 years old, show clinical features with previously reported patients including facial dysmorphism, severe psychomotor retardation, microcephaly, seizures, and gastrointestinal symptoms. Both patients show mutations c.206T > C (p.169 T) and c.626T > C (p.M209T) |
736815 |
| 2.4.1.258 | synthesis |
genetic engineering of N-glycan biosynthesis in Yarrowia lipolytica so that it produces Man(3)GlcNAc(2) structures on its glycoproteins. Disruption of the ALG3 gene, EC 2.4.1.258, results in modification of proteins mainly with Man(5)GlcNAc(2) and GlcMan(5)GlcNAc(2) glycans, and to a lesser extent with Glc(2)Man(5)GlcNAc(2) glycans. To avoid underoccupancy of glycosylation sites, Alg6, EC 2.4.1.267, is concomitantly overexpressed. Overexpression of the heterodimeric Aspergillus niger glucosidase II results in removal the terminal glucose residues. Overexpression of an alpha-1,2-mannosidase leads to Man(3)GlcNAc(2) structures, which are substrates for the synthesis of complex-type glycans. The final Yarrowia lipolytica strain produces proteins glycosylated with the trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core of all complex-type N-glycans |
723575 |
